Argan Inc

AGX is in a pronounced Stage 4 decline, trading well below all major EMAs yet registering extreme oversold readings that qualify for mean-reversion; while the double bottom and bearish exhaustion patterns suggest a potential reversal foundation, execution should be deferred until price shows clear acceptance above short-term EMAs or holds near the defended low support zone.

• ↑Revenue up 50% YoY to $291M in Q1 FY27, exceeding expectations.
• ↑Backlog of $2.8B with guidance to add new projects over next 10–18 months.
• ↓Valuation metrics indicate overvaluation risk for value-focused investors.